Patient Rating:

No Rating Available?

Douglas G. Kondo, M.D.

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 587-1549 Brain Institute
383 Colorow Drive
Salt Lake City, UT 84108
(801) 583-2500 University Neuropsychiatric Institute
Child & Adolescent Psychiatry Research
501 Chipeta Way
Salt Lake City, UT 84108
Map
(801) 582-1565 Veterans Administration Medical Center
500 S Foothill Blvd
Salt Lake City, UT 84149

Bio

Dr. Kondo is a child psychiatrist and brain imaging researcher who works at the Brain Institute and University Neuropsychiatric Institute (UNI). His additional appointments include the Veterans Administration (VA) Salt Lake City Health Care System's Mental Illness Research, Education and Clinical Center (MIRECC), and he is a member of the Utah Science Technology and Research initiative (USTAR) faculty. His research areas inlcude clinical trials, and epidemiologic studies of the effects of altitude on regional rates of completed suicide, psychiatric disorders and substance abuse.

Dr. Kondo's clinical trials research currently focuses on Bipolar Disorder and Major Depressive Disorder, and the brain chemistry changes that are associated with them. Participants are either adolescents, or adult Veterans, and the neuroimaging method used is Magnetic Resonance Spectroscopy (MRS), performed on an FDA-approved clinical MRI scanner that does not use ionizing radiation. MRS is considered safe, which allows for scans to be performed pre-treatment, and then repeated post-treatment, to determine which brain chemiscals are altered as participants recover from either major depression or bipolar depression. The hypothesis underlying this work is that brain energy metabolism is compromised in some children and adults with mood disorders, and that targeting cortical bioenergetics is one potentially effective pharmaceutical treatment strategy.

The epidemiology studies Dr. Kondo works on utilize large, national mental illness and substance abuse data sets collected by the Center for Disease Control and Prevention (CDC). The CDC data are then combined with state and county altitude data from the Space Shuttle Radar Topography Mission (SRTM), conducted by the National Aeronautics and Space Administration (NASA). When analyzed together, the goal of this work is to investigate the association of increasing altitude with state and county rates of psychiatric symptoms, substance abuse and suicide. The underlying hypothesis is that the phenomenon known as "hypobaric hypoxia" may be an unrecognized contributor to the state and local burden of psychiatric illness and substance abuse. For example, local barometric pressure decreases exponentially with altitude. This means that at the altitude of Salt Lake City, Utah or Denver, Colorado, the barometric pressure is approximately 15% lower than at sea level. This results in an equivalent reduction in the partial pressure of oxygen in the inspired air (PIO2). Preclinical studies have shown that hypobaric hypoxia alters the levels of neurotransmitters, including serotonin and dopamine, that have been implicated in mental illness and substance abuse. Dr. Kondo's epidemiology work, and the Brain Institute's animal protocols, are designed to serve as a three-pronged translational research program, in which findings and novel hypotheses resulting from human brain imaging can be tested, and vice-versa.

Prior to joining the Brain Institute, USTAR and MIRECC research teams, Dr. Kondo's previous positions at the School of Medicine included: inpatient child and adult psychiatry at UNI, the Kidstar day treatment program for young children, the adolescent Teenscope day treatment program, and the Neurobehavior H.O.M.E. Program for children and adults with developmental disabilities. He formerly served as Medical Director of UNI's adolescent substance abuse intensive outpatient program. More information regarding Dr. Kondo's current research studies is available at the Internet website: UtahBrain.org.

Board Certification and Academic Information

Academic Departments Psychiatry - Assistant Professor (Clinical)
Academic Divisions Child Psychiatry
Board Certification American Board of Psychiatry & Neurology (Psychiatry)
American Board of Psychiatry & Neurology (Sub: Child/Adol)

Academic Profile

Research Interests

  • Pharmacogenetics
  • ADHD
  • Child Psychiatry
  • Adenosine Triphosphate
  • Depression
  • Psychiatry
  • Mood Disorders
  • Phosphocreatine
  • Adolescent Suicide
  • Nuclear Magnetic Resonance
  • Attention Deficit Disorder with Hyperactivity
  • Genetics
  • Magnetic Resonance Spectroscopy
  • Alcohol and Substance Abuse
  • Anxiety Disorders
  • Creatine
  • Evidence-Based Medicine
  • Psychopharmacology
  • Adolescent Psychiatry
  • Complementary Therapies
  • Depressive Disorder
  • Magnetic Resonance Imaging - MRI
  • Uridine
  • Bipolar Disorder
  • Clinical Trials
  • Clinical Trials Methodology

Board Certification and Academic Information

Academic Departments Psychiatry - Assistant Professor (Clinical)
Academic Divisions Child Psychiatry
Board Certification American Board of Psychiatry & Neurology (Psychiatry)
American Board of Psychiatry & Neurology (Sub: Child/Adol)

Academic Bio

Dr. Kondo obtained his undergraduate degree from the University of Virginia in Charlottesville, then graduated from the University of Utah School of Medicine in 1999. He received his adult psychiatry training at the Menninger Clinic in Topeka, Kansas. He then completed training in Child & Adolescent Psychiatry at Duke University in Durham, North Carolina. Following that, he was a Post-doctoral Fellow in Clinical Research at the Duke Clinical Research Institute (DCRI). Since 2007, he has worked at the University of Utah and the Brain Institute.

Education

Education History

Type School Degree
Postdoctoral Fellowship Duke University Medical Center
Psychiatry
Postdoctoral Fellow
Residency Duke University Medical Center
Psychiatry
Resident
Chief Resident Duke University Medical Center
Psychiatry
Chief Resident
Residency Duke University Medical Center
Psychiatry
Resident
Residency Menninger Clinic
Psychiatry
Resident
Professional Medical University of Utah
Medicine
M.D.
Undergraduate University of Virginia
Philosophy
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Fiedler KK, Kim N, Kondo DG, Renshaw PF (June 2012). Cocaine use in the past year is associated with altitude of residence. Journal of Addiction Medicine, 6(2), 166-71.
  2. Marchant BK, Reimherr FW, Robison RJ, Olsen JL, Kondo DG (2011). Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. J Atten Disord, 15(4), 295-304.
  3. DelMastro K, Hellem T, Kim N, Kondo D, Sung YH, Renshaw PF (2011). Incidence of major depressive episode correlates with elevation of substate region of residence. J Affect Disord, 129(1-3), 376-9.
  4. Kondo DG, Hellem TL, Sung YH, Kim N, Jeong EK, Delmastro KK, Shi X, Renshaw PF (2011). Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder. Depress Res Treat, 2011, 650450.
  5. Kondo DG, Sung YH, Hellem TL, Delmastro KK, Jeong EK, Kim N, Shi X, Renshaw PF (2011). Open-label uridine for treatment of depressed adolescents with bipolar disorder. J Child Adolesc Psychopharmacol, 21(2), 171-5.
  6. Kondo DG, Sung YH, Hellem TL, Fiedler KK, Shi X, Jeong EK, Renshaw PF (2011). Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord, 135(1-3), 354-61.
  7. Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE, Kondo D, Soni P, Robison RJ (2011 Sep). Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. Attention Deficit and Hyperactivity Disorders, 3(3), 237-44.
  8. Robison RJ, Reimherr FW, Marchant BK, Kondo D, Lyon GJ, Olsen J, Christopherson D, Pommerville C, Tuya S, Johnson A, Coon H (July 2010). The Use of Emotional Dysregulation as an Endophenotype for Genetic Studies in Adults With Attention-Deficit/Hyperactivity Disorder. JARD, 1(4), 29-38.
  9. Shapiro M, Silva S, Compton S, Chrisman A, DeVaugh-Geiss J, Breland-Noble A, Kondo D, Kirchner J, and March J (2009). The child and adolescent psychiatry trials network (CAPTN): Infrastructure development and lessons learned. Child Adolesc Psychiatry Ment Health, 3(1), 12-25.
  10. Kondo DG, Speer MC, Krishnan KR, McQuoid DR, Slifer SH, Pieper CF, Billups AV, Steffens DC (2007). Association of AGTR1 with 18-month treatment outcome in late-life depression. Am J Geriatr Psychiatry, 15(7), 564-72.
  11. March JS, Szatmari P, Bukstein O, Chrisman A, Kondo D, Hamilton JD, Kremer CM, Kratochvil CJ (2007 September). AACAP 2005 Research Forum: Speeding the adoption of evidence-based practice in pediatric psychiatry. J Am Acad Child Adolesc Psychiatry, 46(9), 1098-1110.
  12. Kondo DG, Sokol MS (2006). Eating disorders in primary care. A guide to identification and treatment. Postgrad Med, 119(3), 59-65.
  13. Egger HL, Kondo DG, Angold A (2006). The Epidemiology and Diagnostic Issues in Preschool Attention-Deficit/Hyperactivity Disorder: a Review. Infants and Young Children, 19(2), 109-122.
  14. Kondo DG, Chrisman AK, March JS (2003 Summer). An evidenced-based medicine approach to combined treatment of ADHD in children and adolescents. Psychopharmacol Bull, 37(3), 7-23.
  15. Sokol MS, Ward PE, Tamiya H, Kondo DG, Houston D, Zabriskie JB (2002). D8/17 expression on B lymphocytes in anorexia nervosa. Am J Psychiatry, 159(8), 1430-2.
  16. Kondo DG, Bishop FM, Jacobson JA (2000). Residents' and patients' perspectives on informed consent in primary care clinics. J Clin Ethics, 11(1), 39-48.
  17. Kondo DG, Judd VE (2000). Demographic characteristics of US medical school admission committees. JAMA, 284(9), 1111-3.

Book Chapter

  1. Kondo DG, March JS (2004). Attention-deficit Hyperactivity Disorder. In Haas L (Ed.), Handbook of Primary Care Psychology (pp. 215-234). New York: Oxford University Press.

Abstract

  1. Kondo D, Bishop M, and Jaccobson J (1997). Resident Physicians' Understanding and Use of Informed Consent. In: The American Federation for Medical Research, Western Section Annual Meeting [Abstract]. Journal of Investigative Medicine, 45(1), 74A-179A.

Poster

  1. Shi XF, Sung YH, Kondo DG, Carlson P, Hellem TL, Delmastro KK, Kim SE, Zuo C, Jeong EK, Renshaw PF (May 2011). Measurement of Creatine-Kinase Reaction Rate Constant in Human Brain using 31P Magnetization Transfer Image Selected In-Vivo Spectroscopy (MT-ISIS): a Preliminary Application to Bipolar Disorder. Poster session presented at The International Society for Magnetic Resonance in Medicine 2011 Annual Meeting, Montreal, Canada.
  2. Hellem TL, Kondo DG, Renshaw PF (April 2011). Open-Label Uridine for Adolescents with Bipolar Depression: a Proton (1H-MRSI) and Phosphorus (31P-MRSI) Magnetic Resonance Spectroscopy Study. Poster session presented at Western Institute of Nursing 44th Annual Nursing Research Conference, Las Vegas, NV.
  3. Kondo DG, Sung YH, Hellem TL, Delmastro KK, Jeong EK, Kim NK, Shi XF, Renshaw PF (2010). Open-Label Uridine for Adolescent Bipolar Depression: a Magnetic Resonance Spectroscopy Study. Poster session presented at American College of Neuropsychopharmacology 49th Annual Meeting, Miami Beach, FL.
  4. Reimherr F, Marchant BK, Robison RJ, Robison D, Wender P, Williams E, Halls C, Kondo D (June 2010). Psychometric Properties of the Wender-Reimherr Adult Attention Deficit Disorder Scale. Poster session presented at NCDEU 2010 50th Anniversary Meeting, Boca Raton, FL.
  5. Reimerr F, Marchant BK, Olsen JL, Kondo DG, Strong RE, Robison RJ (May 2010). Serotonin Receptor Genes are Associated with Treatment Response and Symptom Severity in Adults with ADHD. Poster session presented at Society of Biological Psychiatry 65th Annual Meeting, New Orleans, LA.
  6. Douglas Kondo MD, YH Sung MD, Namkug Kim PhD, Tracy Hellem RN, Kristen Delmastro BS, and Perry Renshaw MD, PhD, MBA (2009). 31-Phosphorus Magnetic Resonance Spectroscopy (31P-MRSI) Studies of Pediatric Mood Disorders Creatine for Major Depressive Disorder & Uridine for Bipolar Depression: Report of Initial Protocol Completers. Poster session presented at American College of Neuropsychopharmacology Annual 2009 Meeting, Hollywood, FL.

Clinical Trials

Video & News